CV Sciences, Inc. (CVSI)

OTCMKTS: CVSI · Delayed Price · USD
0.0412
-0.0018 (-4.19%)
Jun 24, 2022 4:00 PM - Market closed
-4.19%
Market Cap 5.53M
Revenue (ttm) 19.65M
Net Income (ttm) -14.64M
Shares Out 134.34M
EPS (ttm) -0.13
PE Ratio n/a
Forward PE 15.63
Dividend n/a
Ex-Dividend Date n/a
Volume 169,035
Open 0.0415
Previous Close 0.0430
Day's Range 0.0412 - 0.0448
52-Week Range 0.0400 - 0.4100
Beta 1.21
Analysts Sell
Price Target 0.20 (+385.4%)
Earnings Date May 16, 2022

About CVSI

CV Sciences, Inc. operates as a life science company in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet brand names in various health care sectors, including nutraceutical, beauty care, specialty foods, and pet products. It sells its products through its websites, internet sales, elect dis... [Read more...]

Industry Personal Products
Employees 69
Stock Exchange OTCMKTS
Ticker Symbol CVSI
Full Company Profile

Analyst Forecast

According to 6 analysts, the average rating for CVSI stock is "Sell." The 12-month stock price forecast is 0.2, which is an increase of 385.44% from the latest price.

Price Target
$0.2
(385.44% upside)
Analyst Consensus: Sell
Stock Forecasts

News

CV Sciences, Inc. Reports First Quarter 2022 Financial Results

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products,...

CV Sciences, Inc. Reports Fiscal Year-End 2021 Financial Results

SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) product...

CV Sciences, Inc. to Announce Fourth Quarter and Full Year 2021 Results on March 31, 2022

SAN DIEGO, March 28, 2022 (GLOBE NEWSWIRE) -- CV Sciences, Inc.  (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) produc...

UPDATE -- CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products

New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness New softgels deliver seven times more CBDA and C...

CV Sciences Adds +PlusCBD Relief Softgels to Wellness Line of CBD Products

New softgels deliver seven times more CBDA and CBD than original raw formula to support a healthy inflammatory response and to manage occasional soreness New softgels deliver seven times more CBDA and C...

Dry January Got You Down? Cannabis To The Rescue With Tokes, Yummy Gummies And More

After the hustle and bustle of the holidays, many people are looking to curtail their consumption of alcohol and are therefore partaking in Dry January. Who Thought Of Laying Off Booze For A Month?

CV Sciences, Inc. Announces Launch of +PlusCBD™ Pain Relief Topicals

+PlusCBD™ expands product offerings to include four new topicals that provide targeted pain relief +PlusCBD™ expands product offerings to include four new topicals that provide targeted pain relief

CV Sciences Launches +PlusCBD Pain Relief Topicals With Products For Athletes, Arthritis Patients

CV Sciences, Inc. (OTCQB:CVSI) is launching +PlusCBD Pain Relief topicals. The San Diego-based supplier and manufacturer of hemp cannabidiol (CBD) products confirmed Tuesday that the new line of topical...

CV Sciences, Inc. Appoints Haskell & White LLP as Auditor

SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

Here's Why CV Sciences, Inc. (CVSI) Looks Ripe for Bottom Fishing

CV Sciences, Inc. (CVSI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement amon...

CV Sciences 3Q Financials Continue To Improve Cost Structure, Praises California CBD Legislation

CV Sciences, Inc. (OTCQB:CVSI), a supplier and manufacturer of hemp cannabidiol (CBD) products, announced its financial results for the quarter on Monday, Nov 15. Third Quarter 2021 and Recent Financial...

CV Sciences, Inc. (CVSI) Reports Break-Even Earnings for Q3

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 100.00% and -7.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CV Sciences, Inc. Announces Convertible Note Financing

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

CV Sciences, Inc. Reports Third Quarter 2021 Financial Results

SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

Earnings Preview For CV Sciences

CV Sciences (OTC:CVSI) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors need to know before the announcement.

CV Sciences, Inc. to Announce Third Quarter 2021 Results on November 15, 2021

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

Will CV Sciences, Inc. (CVSI) Report Negative Q3 Earnings? What You Should Know

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CV Sciences, Inc. Applauds the California Legislature for Passage of AB 45

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

CV Sciences, Inc. (CVSI) Reports Q2 Loss, Tops Revenue Estimates

CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 0.00% and 0.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CV Sciences, Inc. Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

CV Sciences, Inc. Receives NutraIngredients-USA 2021 Product of the Year: Immune Support Award

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...

CBD Can Reduce Nicotine Withdrawal Symptoms, Says New Study Done By CV Sciences

This week, CV Sciences (OTCQB:CVSI) released the results of a preclinical study that suggests that CBD can reduce nicotine withdrawal symptoms in smokeless tobacco users. The study, conducted in collabo...

Cantor Updates Ratings On Several Cannabis And CBD Stocks - MedMen, Jushi, cbdMD, CV Sciences

Cantor Fitzgerald's Pablo Zuanic provided updated ratings and estimates on several stocks from the cannabis and CBD sector, those being – MedMen Enterprises (OTCQF: MMNFF), Jushi Holdings (OTCQB: JUSHF)...

Other symbols: YCBD

CV Sciences, Inc. Reports First Quarter 2021 Financial Results

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products,...

Will CV Sciences, Inc. (CVSI) Report Negative Q1 Earnings? What You Should Know

CV Sciences, Inc. (CVSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.